Navigating Non-Product Software Validation in GxP Environments

Yashaswini Maregowda
May 11, 2026

Table of Contents

1. Introduction
2. What Is Non-Product Software?
3. Overlapping Common Expectations
4. Conclusion

1. Introduction

When life sciences organizations talk about software validation, the conversation always gravitates toward product software, embedded device firmware, or clinical trial software that touches the regulated product directly.

There is an equally important category of GxP software that underpins every regulated operation: non-product software. It includes laboratory information management systems (LIMS), quality management systems (QMS), document management platforms, training systems, and AI-driven analytical tools. Even without being part of the product itself, this software must still be validated.

What this blog covers

1. Common Expectations
2. Why It Matters
3. Practical Roadmap

2. What Is Non-Product Software?

Non-product software is any software used in a GxP-regulated environment that does not become part of the product and is not embedded in a medical device. Despite this distinction, it directly influences product quality, patient safety, and data integrity, which is precisely why it falls within the scope of regulatory oversight.

Examples include:

• Quality Management Systems (QMS): CAPA management, deviation tracking, document control, training management, audit management platforms
• Laboratory Systems: LIMS, electronic lab notebooks (ELN), chromatography data systems (CDS)
• Manufacturing Systems: MES, SCADA, building management systems, batch record systems, ERP modules governing GxP operations
• Regulatory & Submission Support Tools: AI/ML models used to analyze manufacturing data, generate statistical summaries, or support regulatory submissions
• Infrastructure & Supporting Software: Backup and restore systems, access management platforms, audit trail repositories, archival systems

3. Overlapping Common Expectations

The 10 Common Expectations

1. Risk-Based Validation & Classification
2. Requirements Management & Lifecycle Traceability
3. Change Control & Impact Assessment
4. Audit Trail & Electronic Records Integrity
5. Testing Strategy Proportionate to Risk
6. Document Lifecycle & Version Control
7. Role-Based Access Control (RBAC)
8. Incident Management & CAPA
9. Vendor & Supplier Qualification
10. Periodic Review & Continued State of Control

Risk-Based Validation & Classification

• FDA CSA replaces the old "validate everything to the same standard" model with a critical-thinking, risk-driven approach.
• FDA AI Guidance for Drugs and Biologics classifies AI models by the influence their output has on regulatory or manufacturing decisions, with higher influence requiring greater rigor in credibility assessment.
• GAMP5 uses its well-established software category framework to stratify validation effort by system complexity and criticality.
• ISO 13485 Clause 7.5.6 requires that software used in production and service provision be validated prior to use, with the extent of validation activities proportionate to the risk associated with the software's use.

Requirements Management & Full Lifecycle Traceability

Every system in scope, from LIMS to your AI-powered process monitoring platform, must have a documented URS that defines what the system is required to do, and a validation package that demonstrates those requirements were met.

Change Control & Impact Assessment

Change control SOP must be written with modern software deployment patterns in mind, not just traditional waterfall patch management.

Audit Trail, Data Integrity & Electronic Records

Every GxP electronic record created, modified, or deleted by a non-product software system must be captured in a secure, computer-generated audit trail.

Testing Strategy Proportionate to Risk

Testing strategy for non-product software must be documented, justified by risk, and evidence-based.

Document Lifecycle Management & Version Control

An undocumented or informally documented validation is not a validation. Every non-product software system must have a controlled, complete, and current validation package.

Access Control, User Roles & Permissions

The access control framework for non-product software must be role-based, documented, and auditable.

Incident Management, CAPA & Deviation Handling

Incident management SOP must explicitly address software and AI system incidents, not just process deviations.

Vendor & Supplier Qualification

Supplier qualification program must be comprehensive, risk-prioritized, and regularly maintained.

Periodic Review & Continued State of Control

Periodic review must define review frequency by system risk category, the data and metrics reviewed, the criteria for determining a system is in a state of control, and the escalation path when it is not.

4. Conclusion

The four frameworks examined here, FDA CSA, the FDA AI Guidance for Drugs and Biologics, GAMP5, and ISO 13485, converge on the same core expectations: risk-based classification, requirements traceability, change control, data integrity, and periodic review. Organizations do not need four compliance programs. They need one program built on this shared architecture, with extensions where a specific framework imposes additional requirements. The goal is not to collect validation documents. The goal is to ensure that every non-product software system in your GxP environment reliably does what it is supposed to do, that you can prove it, and that you will know when it stops.